Epoetin Alfa BS (epoetin alfa biosimilar) / Kissei, JCR Pharma - LARVOL DELTA

INVESTIGATION ON THE CURRENT STATUS SURROUNDING BIOLOGICS AND THE IMPACT OF BIOSIMILARS USING JAPANESE REAL-WORLD DATA IN FY2017 (ISPOR-EU 2019) - "...BS volume proportion of epoetin kappa and filgrastim, insulin glargine, infliximab, somatropine and rituximab were 95.6%, 77.2%, 48.0%, 4.2%, 3.3% and 0.8%, respectively...For biologics with BS available, the proportion of BS use to their costs were inversely related. To control medical expenditure, we recommend that it is just as important to focus on drug costs, in addition to the prescribed volume."

Clinical • Real-World Evidence